Dyadic International (NASDAQ:DYAI) Major Shareholder Sells $79,200.00 in Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 40,000 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $1.98, for a total value of $79,200.00. Following the completion of the sale, the insider owned 3,410,664 shares of the company’s stock, valued at $6,753,114.72. This trade represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Stock Performance

NASDAQ:DYAI opened at $0.94 on Monday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The stock has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $0.83. The firm has a market capitalization of $34.27 million, a PE ratio of -4.09 and a beta of 1.15. Dyadic International Inc. has a 52-week low of $0.65 and a 52-week high of $1.35.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. Analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Dyadic International

Several large investors have recently made changes to their positions in DYAI. Apis Capital Advisors LLC bought a new position in shares of Dyadic International in the third quarter worth about $1,817,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International during the third quarter worth about $190,000. Marathon Capital Management raised its stake in Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 50,000 shares during the period. Geode Capital Management LLC raised its stake in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.